Bruce K Crawford

List of Publications by Year
in descending order

41 papers	2,426 citations	304743 22 h-index	302126 39 g-index
41 all docs	41 docs citations	41 times ranked	3774 citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan. PLoS ONE, 2022, 17, e0269779.	2.5	0
2	The development of the ICIQâ€‘UAB: A patient reported outcome measure for underactive bladder. Neurourology and Urodynamics, 2019, 38, 996-1004.	1.5	7
3	Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. Value in Health, 2019, 22, 267-275.	0.3	98
4	The revalidation of the diabetes treatment-related quality-of-life (DTR-QOL) questionnaire in Japan. Diabetology International, 2019, 10, 93-101.	1.4	3
5	Neuropathic pain: A patientâ€‘centred approach to measuring outcomes. Health Expectations, 2018, 21, 774-786.	2.6	7
6	Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan. Journal of Atherosclerosis and Thrombosis, 2018, 25, 580-592.	2.0	13
7	Mapping to Estimate Health-State Utility from Nonâ€"Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report. Value in Health, 2017, 20, 18-27.	0.3	145
8	Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan. Clinical Therapeutics, 2017, 39, 738-750.e4.	2.5	18
9	Impact of Pediatric Acute Otitis Media on Child and Parental Quality of Life and Associated Productivity Loss in Malaysia: A Prospective Observational Study. Drugs - Real World Outcomes, 2017, 4, 21-31.	1.6	12
10	The Use of patient Reported Outcome Measures for Rheumatoid Arthritis in Japan: A Systematic Literature Review. Open Rheumatology Journal, 2017, 11, 43-52.	0.2	6
11	Optimal Treatment for Complicated Intra-abdominal Infections in the Era of Antibiotic Resistance: A Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Therapy With Metronidazole. Open Forum Infectious Diseases, 2016, 3, ofw143.	0.9	13
12	WILLINGNESS TO PAY FOR LUNG CANCER TREATMENT: PATIENT VERSUS GENERAL PUBLIC VALUES. International Journal of Technology Assessment in Health Care, 2015, 31, 264-270.	0.5	8
13	Utilization patterns of insulin therapy and healthcare services among Japanese insulin initiators during their first year: a descriptive analysis of administrative hospital data. BMC Health Services Research, 2015, 16, 6.	2.2	9
14	Economic Burden of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery. Value in Health Regional Issues, 2015, 6, 73-79.	1.2	5
15	Validation of a COPD screening questionnaire and establishment of diagnostic cut-points in a Japanese general population: The Hisayama study. Allergology International, 2015, 64, 49-53.	3.3	25
16	Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies. Journal of Cardiology, 2015, 66, 466-474.	1.9	36
17	Economic Impact of Venous Thromboembolism Following Major Orthopaedic Surgery in Japan. Value in Health Regional Issues, 2013, 2, 81-86.	1.2	4
18	Hepatitis C virus in Asia: utility values based on the Short Form-36 questionnaire. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 765-773.	1.4	4

#	Article	IF	Citations
19	Evaluation of the willingness‐to‐pay for cancer treatment in Korean metastatic breast cancer patients: A multicenter, cross‐sectional study. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 282-291.	1.1	18
20	PRO development: rigorous qualitative research as the crucial foundation. Quality of Life Research, 2010, 19, 1087-1096.	3.1	347
21	Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis. Respiratory Medicine, 2010, 104, 534-541.	2.9	26
22	Validation of the sleep impact scale in patients with major depressive disorder and insomnia. Current Medical Research and Opinion, 2009, 25, 1699-1710.	1.9	7
23	Bayesian Meta-Analysis of Multiple Treatment Comparisons: An Introduction to Mixed Treatment Comparisons. Value in Health, 2008, 11, 956-964.	0.3	283
24	Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. British Journal of Haematology, 2008, 143, 511-519.	2.5	55
25	Conceptual adequacy of the neuropathic pain symptom inventory in six countries. Health and Quality of Life Outcomes, 2008, 6, 62.	2.4	32
26	Development and validation of a cough and sputum assessment questionnaire. Respiratory Medicine, 2008, 102, 1545-1555.	2.9	67
27	Development of the ASK-20 Adherence Barrier Survey. Current Medical Research and Opinion, 2008, 24, 2127-2138.	1.9	91
28	Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 317-326.	1.4	72
29	Fexofenadine Improves the Quality of Life and Work Productivity in Japanese Patients with Seasonal Allergic Rhinitis during the Peak Cedar Pollinosis Season. International Archives of Allergy and Immunology, 2005, 136, 148-154.	2.1	56
30	Quality-of-life improvements in cataract patients with bilateral blue light–filtering intraocular lenses: Clinical trial. Journal of Cataract and Refractive Surgery, 2005, 31, 1952-1959.	1.5	55
31	Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 590-601.	2.0	68
32	Use of Quality Adjusted Life Years and Life Years Gained as Benchmarks in Economic Evaluations: A Critical Appraisal. Health Care Management Science, 2004, 7, 43-49.	2.6	73
33	Usefulness of resource utilization estimates from piggyback studies in rheumatoid arthritis. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 685-689.	1.4	0
34	Meeting the US FDA's evidence standard with health-related quality of life claims. Expert Review of Pharmacoeconomics and Outcomes Research, 2002, 2, 401-402.	1.4	2
35	Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate. Annals of Internal Medicine, 2002, 137, 726.	3.9	287
36	Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis and Rheumatism, 2000, 43, 506.	6.7	155

#	Article	IF	Citations
37	Data Collection Methods in Prospective Economic Evaluations: How Accurate Are the Results?. Value in Health, 2000, 3, 277-286.	0.3	23
38	Direct Medical Costing for Economic Evaluations: Methodologies and Impact on Study Validity. Drug Information Journal, 2000, 34, 173-184.	0.5	5
39	Expert Judgement in Pharmacoeconomic Studies. Pharmacoeconomics, 2000, 17, 545-553.	3.3	34
40	Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis and Rheumatism, 1999, 42, 1870-1878.	6.7	132
41	Patient Self-Reports in Pharmacoeconomic Studies. Pharmacoeconomics, 1999, 15, 241-256.	3.3	125